small sums of money available to support research then raising more with countrywide appeals. One of his proudest achievements was to promote the emergence of the Medical and Scientific Section of the BDA.
Within weeks of his appointment as Secretary General of the BDA in 1953, Jim was detailed to undertake the local organisation of the Second IDF Congress in Cambridge UK in 1955 and was soon hobnobbing with the diabetes greats of the era, among them F G Young, E P Joslin, C H Best, J P Hoet (Sr) and of course his immediate chief, R D Lawrence. The Cambridge meeting -housed in a single lecture theatre -was a great success, but 1955 had even greater significance for Jim. That year, he married Nancy, beginning a partnership of immense importance to them both.
Help with a succession of IDF Congresses followed, Duesseldorf in 1958 and Geneva in 1961. Three years later, at the Toronto IDF Congress, Jim was invited by Albert Renold to involve himself in the discussions called within a group of European delegates about the organisation of a European Association for the Study of Diabetes. He subsequently helped create its administrative structures and set up its first meeting in Montecatini, Italy, the following year. He continued to underpin the administration of EASD and in 1970 was formally appointed its first Director General. The debt to Jim was well expressed by Albert Renold when he wrote as he left the EASD Presidency in October 1977 "The EASD began without you (today one wonders how) but it surely would not have charted the steady course it did, and does, without your steady sailor's hand at the helm.", a sentiment endorsed by the conferment upon him of an MD honoris causa of the University of Geneva in 1979 and Honorary Membership of EASD at his retirement as Director Executive in 1988.
Any appreciation of Jim is incomplete without the inclusion of Nancy. Both were tireless in their commitment to the welfare of the members of the Association, travelling cross country to children's camps, speaking at faraway Branch meetings, ensuring that events ran smoothly, whether handing out badges, welcoming visiting dignitaries, fixing accommodation for unexpected arrivals or finding answers to abstruse questions about employment or food. Together, they visited the Americas, Australia, India, Africa, always a friendly and welcome presence and delighting in the Honorary Membership of IDF Jim received (on their joint behalf) in Helsinki in 1997.
The abiding memory will be of a precise, well turned out -even dapper -character, respectful without being deferential, correct but unbureaucratic, with high expectations both of himself and of others. Sometimes seemingly unbending, there were few who spent more than a few minutes in his company before recognising his warmth, commitment and loyalty.
Much that we now take for granted in the procedures and activities of our diabetes organisations was conscientiously put in place by Jim Jackson decades ago and has served us well ever since. It is the richness and strength, the success and durability of these organisations that constitute Jim's real memorial, and he would ask none better. In reaching their decision, the members of the Committee will be looking for candidates with some experience in research and who work in an academic environment favourable to diabetes research. A letter of support from the head of the academic department will be considered an essential part of the application.
Harry
The EASD Sub-committee responsible for the EASD Scientists Training Course is chaired by Drs. Geremia B. Bolli (Chair) and Claes Hellerström (Cochair). The Course will be held in English. It is understood that all applicants must thus be able to communicate in this language. All participants will be required to attend the entire Course. There will be no exception to this rule.
Venue
The ninth Course will be hosted by the Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany. Hannover is located in the Northern part of Germany with excellent accessibility by aeroplane and train.
Organisers
The Course is organised by Prof. Sigurd Lenzen and Dr Markus Tiedge.
Format
A hands-on practical course will be provided for a maximum of 16 participants who will rotate in groups of 4 through laboratories at the institute. Each day will typically begin with a lecture outlining the theoretical and practical issues and an overview of the day's work.
Focus
This Training Course we will provide insights into a broad range of modern molecular biology techniques in diabetes research with particular emphasis on pancreatic islet research. The course will include modules of theoretical introductions, practical experimentation and feedback discussions. Emphasis will be given to technical procedures that would be difficult to learn without direct instruction. Applicants should be interested in the molecular aspects of islet diabetology and should have basic laboratory skills and a theoretical background in basic molecular biology. The Course is open to all members of the EASD and is designed as an introduction to enter this area of research, or for more experienced researchers from other fields who wish to obtain some basic training in this area.
Cost of the Course
Applicants will be asked to pay Euro 240,-registration fee, as well as their transportation to and from Hannover, Germany. All other expenses including board and lodging will be covered by EASD funds, supported by Eli Lilly. Each applicant will be evaluated for eligibility and following individual requests, the registration fee may be waived. In exceptional circumstances and following a formal application, the EASD may, if necessary, also provide a travel grant. After the registration, the meeting was opened with a warm welcome from PSAD President Dr. Frank Snoek (The Netherlands) and Dr. Karin Kanc (Slovenia). Dr. Jon Haug (Norway) then delivered the Anita Carlson Keynote Lecture entitled: "An important intervention in Type 1 diabetes is to create a psychological need for insulin in order to prevent omission of insulin injections. How do we do it?" This invited lecture was a fascinating insight into Jon Haug's theory that through the founding of a 'personal owned regulatory system' for insulin injection, which is rooted in self-determined evaluations and actions, we can increase the likelihood of forming positive feelings towards insulin in patients with diabetes. That evening we were treated to a delicious dinner at the hotel, located near the beautiful emerald-green lake of Bled.
Application procedures
Day two opened with group work, discussing the theoretical and clinical implications of Haug's presentation, followed by a plenary discussion. Next, in his own energetic and enthusiastic way, Sören Skovlund (Denmark) presented thought-provoking and novel data from the DAWN study, a global study of psychosocial issues in diabetes, initiated by Novo Nordisk. After a coffee break, the meeting continued with an excellent presentation by Marcel Adriaanse (The Netherlands), who reported on preliminary results from a large population-based study on the short term psychological impact of diagnosis of Type 2 diabetes. After differences in corresponding baseline scores had been adjusted for, significantly lower levels of Energy (WBQ-12) were found for screening detected subjects, compared to those with a negative test-result, who were otherwise comparable. As the differences found were significant but small, Marcel concluded that the short-term psychological impact of the diagnosis Type 2 diabetes seems limited. Dr. Frans Pouwer (The Netherlands) then presented data from a population-based Dutch study on the prevalence of co-morbid depression in the elderly with Type 2 diabetes. It was concluded that Type 2 diabetes was associated with an increased risk of depression and that the presence of diabetes-related complications probably plays an important role in the aetiology of depression in Type 2 diabetes.
After lunch, Dr. Chas Skinner (UK) presented data from a fascinating and innovative pilot study on the development and evaluation of a psycho-educational workshop for patients with newly diagnosed Type 2 diabetes, that recently won the Bayer Diagnostic Diabetes UK 2001 Education Award. It was concluded that participants reported their illness to be more serious after the workshop than before, and they initiated appropriate behaviour changes. Next, the interesting and highly relevant question "How can we sustain behaviour change?" was discussed.
The final, and perhaps most provocative, presentation of the day was by Alison Woodcock (UK), who described data on the use of the Diabetes Tablet Treatment Questionnaire (DTTQ), that is designed to identify patients who might benefit from a switch to sulphonylurea treatment once-a-day. That Saturday evening we were treated to a delightful Slovenian dinner with traditional Slovenian music.
On Sunday, the final session of the study group meeting was opened by Dr. Mirjana Pibernic-Okanovic (Croatia), who presented novel data on a controlled clinical trial that studied the effects of an 'empowerment'-based psychosocial intervention, building on the work of Dr. R.M. Anderson from the USA. Dr. Pibernic-Okanovic described that the intervention group reported improvements in both quality of life and glycaemic control at 3 and 6 months follow up. However, further improvements in glycaemic control were still desirable, and it appeared that patients with higher education benefited the most from the intervention. Jane Speight (UK) then gave an excellent presentation on the results of the DAFNE study. It is well known that dietary restriction is a major burden to people with Type 1 diabetes. The aim of the DAFNE (Dose Adjustment For Normal Eating) Trial was to evaluate 'The Duesseldorf' approach to managing diabetes that offers insulin adjustment skills training, enabling people to have the freedom to eat as they wish while maintaining or even improving glycaemic control. Jane Speight shared very interesting preliminary data of the DAFNE Study with the participants of the PSAD Spring meeting and described that the increased flexibility offered by this approach led to major and lasting improvements in treatment satisfaction, psychological well-being and quality of life.
Dr. Laura Ruggiero (USA) is an expert on the Trans Theoretical Model (TTM) and explained her model to the participants of the meeting. She described the different stages of behaviour change and its relevance to diabetes: pre-contemplation, contemplation, preparation, action and maintenance and its clinical utility. She also described her current research, that is focused on large scale clinical trials examining the impact of stage-matched and individualised intervention approaches targeting multiple health behaviours in people with diabetes.
With her Italian charm, Palma Bregani (Italy) presented data on a complex programme of psychological interventions in young adolescents (aged 11-14) with diabetes. The programme was designed to help these adolescents to improve their body image, stimulate their sense of autonomy and to improve their social skills.
The meeting was closed by Dr. Frank Snoek, with expressions of gratitude to Dr. Karin Kanc, Dr. Maja Ravnik Oblak and Nico Arneric, for organising the meeting and showing the participants (some of) the beauty of this small country. The overall impression was of another exciting and thought-provoking meeting that enhanced the profile of the PSAD Study Group as an excellent forum for experienced and more junior researchers alike to present data, with the focus placed firmly on lively debate and constructive comment. 
Report on an EFSD / MSD Travel Fellowship for Young Scientists
The following is a short report on my work during my stay at the Joslin Diabetes Center of Harvard Medical School in Boston at the laboratory of the Director and President of the institute: Dr. C. Ronald Kahn.
During my stay in the Dept. for Cellular and Molecular Physiology I was working with Dr. Rohit N. Kulkarni. I was involved in several of the projects currently under investigation. This included studies of insulin-receptor-knock-out-models in different tissues and furthermore double-knock-out-studies affecting additional genes besides the insulin receptor which originate from earlier works performed in this laboratory.
To generate the tissue-specific knock-out, Dr. Kulkarni applied the cre/lox-technique. Study-groups of animals were set up following the results of PCRgenotyping performed by the recipient consisting of knock-outs, heterozygous knock-outs and control animals.
Techniques applied during this period included glucose and insulin tolerance tests (GTT, ITT) in fasted and random fed state respectively, as well as treatments to monitor development of blood-glucose-levels, body-weight and other characteristics of growth on a long term scale.
Furthermore, to analyze acute phase insulin release, volumes of blood were collected in a glucose stimulated insulin secretion test (GSIS) after 0, 2, 5 and 15 minutes of intraperitoneal glucose injection. From those probes, serum was derived for insulin-ELISA and glucagon-RIA, which were also performed by me, to give further evidence of alterations in the metabolic state of the knock-out animals compared to the unaffected wildtype-group. These tests were to be repeated with other non-carbohydrate compounds (e.g. amino acids).
Using another approach, newborn mice of the double-knock-out-study, were dissected to isolate pancreas and liver-biopsies. I was able to gain some experience in this technique.
After fixation in formaline and paraffin-embedding, the samples were treated with immunostaining to give a more detailed impression of the distribution of hormones (i.e. glucagon, insulin) in cellular components. Comparison between the very young and older (diabetic, obese) animals followed to gain insights of the metabolic changes during adulthood. The opportunity was given to me to assist in several steps of this process.
During this time, I was also trained regarding the techniques of isolation and transplantation of murine Islets of Langerhans. These techniques are used to identify the primary effects on the various knock-outmodels under investigation at the laboratory of Dr. Kulkarni. The results help to distinguish whether the altered metabolic patterns are due to alterations in glucose metabolism or a direct consequence of beta-cell apoptosis.
To isolate such islets, the anesthetized mouse is prepared with an abdominal incision to expose the pancreas. The pancreatic duct is prepared and liberated of surrounding tissue. A canule is inserted in the duct while the insertion to the duodenum must be tied off. Slowly, a solution of the enzyme collagenase or alternatively liberase is injected into the pancreas. This requires, depending on effectiveness, a volume of 2 ml. After complete dilation of the pancreas, it can be removed and stored on ice for the further isolation process.
Islets can be cultured overnight before further use the next day. A proposed procedure is the digestion of the islets to obtain single cells. To quantify the proportions of the cell types in the digested islet, a fluorescence-based cell-sorting process follows.
T.J. Schulz, German Institute of Nutrition, Potsdam, Germany
Transplantation was used to bring the islets into healthy mice. For this process, an amount of 100 islets per kidney capsule should be used. Through an incision in the skin layer, the kidney is identified beneath the tissue. The kidney is pushed out of the capsule through a puncture in the muscle tissue. Islets can now be injected under the capsule after making a small incision into the capsule at the lower end. The implanted islets are supported by the surrounding tissue. Metabolic parameters can be determined with the techniques mentioned above.
In addition to the scientific work, I was invited to join scientific meetings of the different laboratories within Dr. Kahn's department. Thus I learned about new techniques applied in the laboratory to create new models of gene-disruption and about progresses in in vivo glucose measurements. Part of this was also a presentation by Mrs. V.F. Duvivier-Kali, M.D., a member of a Joslin Diabetes Center research group, about new results in transplantation of microencapsulated islets. Normal glycemia re-established after transplantation of islet-grafts encapsulated in biocompatible capsules of a BaCl 2 -crosslinked alginate. No immunorejection occurred and thus the islet-survival was prolonged in a significant manner even in islets from different species.
During the stay, I also had the opportunity, to visit the laboratory of Dr. Helen Vlassara at the Division of Experimental Diabetes and Aging of the Mount Sinai Medical School of New York University. In this laboratory, I was able to learn about techniques to determine Advanced Glycation Endproducts (AGEs), which are currently under investigation in the laboratory.
Also on behalf of Drs. A.F.H. Pfeiffer and M. Ristow at the German Institute for Human Nutrition and the Free University of Berlin, I would like to take this opportunity to thank the EFSD for the support. This Travel Fellowship provided me with a unique opportunity for an extension of my scientific training.
Tim Julius Schulz Potsdam, Germany

Report on an EFSD/MSD Travel Fellowship for Young Scientists
Marina Trento Dipartimento di Medina Interna and Centro Retinopatia Diabetica Università degli Studi di Torino, Italy
July and December 1999: 1 month, July 2000: 12 days stay at the Bro Taf Health Authority, Diabetic Retinopathy Screening Service (DRSS), Llandough Hospital, Wales.
Diabetic retinopathy (DR) is one of the leading causes of visual loss in industrialized countries. Prevention of diabetes-related blindness rests upon optimised control of blood glucose and blood pressure. However, optimal metabolic and pressure control is not always achieved and, even among patients well within treatment targets, DR may develop and progress. Hence, active screening procedures are being deployed in many countries to ensure that sight-threatening DR (STDR) can be recognized and promptly treated by laser photocoagulation before it has caused visual impairment.
Patients may not associate diabetes with increased risk for eye problems. In addition, while screening in our Diabetic Retinopathy Centre in Turin, we observed that many patients do not recall having had their eyes examined, or even having had laser treatment, a few months after their last visit or from one year to the next. Screening for DR is a cumbersome, time-consuming procedure for people with diabetes, who have to undergo a short interview, measurement of visual acuity, often pupil dilatation and the intense light of instruments (ophthalmoscopes, retinal cameras or slit lamps) used by the operators. As a result, some patients are unwilling to have their eyes checked and may default their appointments.
Success of prevention strategies depends as much on proper organization and instrumentation of health care delivery as it does on cooperation on the part of the patients. Very little is known about patients' awareness of the risks posed by DR and of their potential role in preventing the worst visual outcomes.
My stay in the Bro Taf Health Authority, Diabetic Retinopathy Screening Service (DRSS), Llandough Hospital, Wales, UK, enabled me to explore these as-pects not only in Northern Italian but also Welsh patients undergoing routine screening for STDR, according to the same European Field Guide-Book protocol.
One-hundred and thirty consecutive patients in Turin and 128 in Wales were administered a specially designed questionnaire, soon after screening for STDR in local facilities. Informed consent was obtained from the patients prior to administering the questionnaire and none refused to answer it. Patients in Wales (group W) were mostly seen by their general practitioners and participated in a community screening programme carried out by mobile fundus cameras driven to local health facilities. Forty-seven of them were being screened for the first time, whereas 81 had already been screened at least once before. Patients in Turin were mostly followed as outpatients by diabetes clinics based in the hospital in which screening was carried out. They had all been screened at least once before. Seventy were on standard individual diabetes care (group T1), whereas 60 (group T2) had been enrolled for at least 2 years in a programme of group care delivery based upon systemic education in which I am personally very involved and that may have a positive impact on the patients' health beliefs of and locus of control. After visual acuity and pupil dilatation colour photographs of 2 x 45°fields (macula and nasal to disc) were taken using Canon CR6-45NM digital fundus cameras. The patients were then informed of the results of screening through their habitual diabetes care providers. After completion of the screening procedure, the patients were asked to answer a specific questionnaire, which I had prepared before moving to Wales, comprising both open and multiple-choice questions. The questionnaire aimed at verifying what the patients remembered of the screening visit and the steps they had just undergone (mydriasis, fundus photography), by a set of closed questions, what knowledge/impression they had of the human retina and DR, by both open and multiple-choice questions supported by a standard fundus photograph, and by open questions where the locus of control is for prevention of diabetes-related blindness.
Of the Welsh patients, 51 (39.8%) had been referred to the screening clinic by their general practitioner, 12 (9.4%) by their diabetes specialist and the remainder from other sources (optician, personal letter from the Screening Service). In Turin, all patients had been referred by their diabetologists as part of the customary yearly screening for complications. Fewer patients in Wales (65%) than in group T1 (84%) answered that they believed that diabetes can damage their eyesight and had heard of diabetic retinopathy. All patients in group T2 said they were aware of both. Sixteen percent of patients in Wales and 19% in group T1 could provide a meaningful description of DR, as judged in a non-standardised fashion (e.g. "a disease of the back of the eye"), compared with 82% of those in group T2. Seventeen percent of the latter and none in groups T1 and W could use correctly the word "retina" within context. Forty-seven percent of Welsh patients and 57% of those in group T1 answered there was nothing they could do to help saving their own eyesight from diabetes-induced damage, compared with 1 patient in group T2 (p<0.001). Patients in the latter group were definitely more aware of the active role they could play in preventing eye damage by regularly attending the diabetes clinic and/or having their eyes checked (p<0.001, both answers). Only 9% of patients in Wales were aware that the screening visit they just had was meant to prevent diabetes-related blindness, against 61% in group T1 (p<0.001) and all those in group T2.
With reference to their role in managing their own diabetes, 64% of Welsh patients and 68% of those in group T1 either did not reply, felt they could not help or said they would passively follow their doctor's directions. On the contrary, all patients managed by group care (T2) felt they could take matters into their hands by appropriate eating habits, exercise and, for those who had been instructed in it, home monitoring of blood glucose.
Finally, the patients were shown a colour print of a fundus photograph reproducing a normal human retina and asked whether they knew what it represented. Independently of the group they belonged to, only a minority of patients identified it as reproducing a part of the eye (W=31%; T1=24%; T2=28%), whereas most others provided such varied replies as: an orange, the sun, the moon, a fried egg, a breast with nipple, a football or a spider or others.
These results confirm that a wide gap exists between patients' knowledge and expectations on retinopathy on the one side, and health operators' expertise and assumptions on the other. To bridge this gap, structured education approaches may be much more effective than simple information given during standard consultations. Patients followed by group care appeared to have acquired a deeper understanding of their diabetes, ways of controlling it and its complications. Thus, continuous education may have improved cooperation between patients and the diabetes team. That group care promoted correct beliefs and shifted the locus of control could account, at least in part, for why this technique is effective in maintaining good metabolic control and improving quality of life.
My stay in Cardiff was not only scientifically very valuable, but also a great personal experience. I would like to express my deep gratitude towards Professor D.R. Owens and his team at "Bro Taf Health Authority, Diabetic Retinopathy Screening Service (DRSS), Llandough Hospital, Wales". The paper I wrote was the winner of the "Diabetes Award for the best abstract on therapeutic patient education" submitted to the 37 th EASD Annual Meeting (2001) Major Programme Topics -β-cell signaling including ionic and metabolic events -K-ATP-dependent and independent pathways, and exocytosis -Apoptosis (mechanisms and prevention) -Stem cells
